Studying Gene Expression in Samples From Younger Patients With Neuroblastoma

NCT01553448 | Completed

• 4 other identifiers: ANBL12B6COG-ANBL12B6CDR0000728527NCI-2012-00706
• Study Type: observational
• Target: 75
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in samples from younger patients with neuroblastoma.

Conditions

Neoplastic Syndrome; Neuroblastoma

Keywords

disseminated neuroblastoma; hereditary neuroblastoma; localized resectable neuroblastoma; localized unresectable neuroblastoma; stage 4S neuroblastoma

Outcome Measures

Primary Outcomes (2)

• Expression of TβRIII in the neuroblastic tumor and stroma of patients with advanced-stage NBL

• Correlation between TβRIII levels and TGF-β signaling correlate with NBL stage, tumor stroma content, surface TβRIII expression, and TGF-β signaling

Interventions

gene expression analysis GENETIC

protein expression analysis GENETIC

enzyme-linked immunosorbent assay OTHER

immunohistochemistry staining method OTHER

laboratory biomarker analysis OTHER

medical chart review OTHER

Eligibility Criteria

• Age: Up to 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients with low-stage (International Neuroblastoma Staging System \[INSS\] stage 1 or 2) neuroblastoma (NBL), patients with advanced-stage (INSS stage 3 or 4) NBL, or patients with stage 4S NBL

DISEASE CHARACTERISTICS: * Tissue samples and matched plasma samples available from 1 of the following groups: * Patients with low-stage (International Neuroblastoma Staging System \[INSS\] stage 1 or 2) neuroblastoma (NBL) * Patients with advanced-stage (INSS stage 3 or 4) NBL * Patients with stage 4S NBL * Clinical and/or outcome data associated with the tissue and plasma samples including INSS stage, age, MYCN amplification status, chromosomal alterations, and 5-year survival, if known PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Children's Oncology Group: lead
• National Cancer Institute (NCI): collaborator

MeSH Terms

Conditions

Neoplasms; Neuroblastoma

Interventions

Gene Expression Profiling; Enzyme-Linked Immunosorbent Assay; Immunohistochemistry

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors, Primitive, Peripheral; Neuroectodermal Tumors, Primitive; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Genetic Techniques; Investigative Techniques; Immunoenzyme Techniques; Immunoassay; Immunologic Techniques; Immunosorbent Techniques; Molecular Probe Techniques; Histocytochemistry; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Histological Techniques

Study Officials

• Gerard C. Blobe, MD, PhD

  Duke University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 13, 2012
• First Posted: March 14, 2012
• Study Start: March 1, 2012
• Primary Completion: May 1, 2016
• Last Updated: May 18, 2016

Record last verified: 2016-05